135 related articles for article (PubMed ID: 35398717)
1. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.
Stares M; Ding TE; Stratton C; Thomson F; Baxter M; Cagney H; Cumming K; Swan A; Ross F; Barrie C; Maclennan K; Campbell S; Evans T; Tufail A; Harrow S; Lord H; Laird B; MacKean M; Phillips I
ESMO Open; 2022 Apr; 7(2):100445. PubMed ID: 35398717
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab.
Stares M; Doyle E; Chapple S; Raynes G; MacDonald J; Barrie C; Laird B; MacKean M; Philips I
Lung Cancer; 2024 Mar; 189():107497. PubMed ID: 38295631
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
[TBL] [Abstract][Full Text] [Related]
4. Sixth-Week Immune-Nutritional-Inflammatory Biomarkers: Can They Predict Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
Olgun P; Diker O
Curr Oncol; 2023 Dec; 30(12):10539-10549. PubMed ID: 38132403
[TBL] [Abstract][Full Text] [Related]
5. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases.
Asano Y; Hayashi K; Takeuchi A; Kato S; Miwa S; Taniguchi Y; Okuda M; Matsumoto I; Yano S; Demura S
Int Immunopharmacol; 2024 Jul; 136():112276. PubMed ID: 38820958
[TBL] [Abstract][Full Text] [Related]
6. Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Ruggeri EM
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275894
[TBL] [Abstract][Full Text] [Related]
7. Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancer.
MacDonald M; Poei D; Leyba A; Diep R; Chennapan K; Leon C; Xia B; Nieva JJ; Hsu R
Cancer Treat Res Commun; 2023; 36():100752. PubMed ID: 37611343
[TBL] [Abstract][Full Text] [Related]
8. PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.
Dimitrakopoulos FI; Nikolakopoulos A; Kottorou A; Kalofonou F; Liolis E; Frantzi T; Pyrousis I; Koutras A; Makatsoris T; Kalofonos H
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429368
[TBL] [Abstract][Full Text] [Related]
9. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
Jiang H; Li B; Wu M; Wang Q; Li Y
BMC Cancer; 2024 Apr; 24(1):428. PubMed ID: 38589844
[TBL] [Abstract][Full Text] [Related]
10. EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Prelaj A; Ferrara R; Rebuzzi SE; Proto C; Signorelli D; Galli G; De Toma A; Randon G; Pagani F; Viscardi G; Brambilla M; Trevisan B; Ganzinelli M; Martinetti A; Gallucci R; Di Mauro RM; Molino G; Zilembo N; Torri V; de Braud FM; Garassino MC; Lo Russo G
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817541
[TBL] [Abstract][Full Text] [Related]
11. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
Saal J; Bald T; Eckstein M; Ralser DJ; Brossart P; Ellinger J; Hölzel M; Klümper N
Lung Cancer; 2024 Mar; 189():107505. PubMed ID: 38367405
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Glasgow Prognostic Score in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Meta-Analysis.
Wang H; Yang R; Cheng C; Wang S; Liu D; Li W
Nutr Cancer; 2024; 76(2):187-195. PubMed ID: 38140926
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer.
Lee S; Eo W; Jeon H; Park S; Chae J
J Cancer; 2017; 8(15):2974-2983. PubMed ID: 28928889
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics.
Yolchuyeva S; Ebrahimpour L; Tonneau M; Lamaze F; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VS
J Transl Med; 2024 Jan; 22(1):42. PubMed ID: 38200511
[TBL] [Abstract][Full Text] [Related]
15. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
Tanabe K; Kobayashi S; Maezawa Y; Ishihara K; Inoue N; Izumi K; Fujiwara M; Toide M; Yamamoto T; Uehara S; Araki S; Inoue M; Takazawa R; Numao N; Ohtsuka Y; Tanaka H; Yoshida S; Fujii Y
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38833113
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy.
Sung M; Jang WS; Kim HR; Park JA; Lim SM; Kim HR; Cho BC; Park YR; Hong MH
Transl Lung Cancer Res; 2023 Jul; 12(7):1506-1516. PubMed ID: 37577328
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Mokbel S; Baciarello G; Lavaud P; Omlin A; Calabrò F; Cathomas R; Aeppli S; Parent P; Giannatempo P; Koster KL; Appel N; Gonnet P; Angius G; Tsantoulis P; Arkenau HT; Cattrini C; Messina C; Zeghondy J; Morelli C; Loriot Y; Formica V; Patrikidou A
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672547
[TBL] [Abstract][Full Text] [Related]
18. Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer.
Rochigneux P; Lisberg A; Garcia A; Granjeaud S; Madroszyk A; Fattori S; Gonçalves A; Devillier R; Maby P; Salem N; Gorvel L; Chanez B; Gukasyan J; Carroll J; Goldman J; Chretien AS; Olive D; Garon EB
Clin Cancer Res; 2022 Dec; 28(23):5136-5148. PubMed ID: 36166003
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor score (IChIS) predicts survival benefit of immunotherapy in patients with non-small cell lung cancer.
Kang DH; Choi CM; Park CK; Oh IJ; Kim YC; Yoon SH; Kim Y; Lee JE
Tuberc Respir Dis (Seoul); 2024 May; ():. PubMed ID: 38749491
[TBL] [Abstract][Full Text] [Related]
20. Significance of preoperative evaluation of modified advanced lung cancer inflammation index for patients with resectable non-small cell lung cancer.
Sato S; Sezaki R; Shinohara H
Gen Thorac Cardiovasc Surg; 2024 Jan; ():. PubMed ID: 38246904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
